Standish Fleming is a 29-year veteran of early stage life sciences investing. He has helped raise and manage six venture capital funds totaling more than $500 million, and has served on the boards of 19 venture-backed companies, including Nereus Pharmaceuticals, Ambit Biosciences, Triangle Pharmaceuticals (acquired by Gilead Sciences) and Actigen/Corixa (now part of GSK).
He has extensive experience in all aspects of venture management and finance, including fund-raising, investor relations, operations and portfolio development. He has made investments, managed portfolio companies, raised funds, pursued business development, taken companies public and successfully exited investments through public-market sales and buyouts. In 1993, Mr. Fleming co-founded San Diego's Forward Ventures. He has made investments in almost every segment of the health-care industry, including pharmaceuticals, biologics, diagnostics, devices, services, and software. He has managed both platform and product companies, portfolio investments, and led or participated in financings at all levels, from pre-startup to PIPES in public companies, in both debt and equity. He has helped start more than 15 companies and served as founding CEO of eight. Fleming serves as a director of CONNECT, San Diego's support organization for the early-stage community, and is a past president of the Biotechnology Venture Investors Group. Before establishing Forward Ventures, He served as the chairman, president and CEO of GeneSys Therapeutics, (merged with Somatix and acquired by Cell GeneSys [NASDAQ:CEGE]). Fleming began his venture career with Ventana Growth Funds in San Diego in 1986. He earned his B.A. from Amherst College and his M.B.A. from the UCLA Graduate School of Management.
When President Obama forced Pfizer to scrap its proposed $160 billion merger with Allergan, the industry as well as the company emerged as losers in the eyes of the public, despite... Read more »
Biotech is riding the crest of a wave of public and private financial interest unparalleled in the 36-years since the founding of Genentech. Since 2012 public markets have committed $10.3 billion... Read more »
Xconomy’s Luke Timmerman recently suggested that biotechs’ IPO option has shifted the balance of power between Big Pharma and biotech closer to parity, and the big guys have lost (or at... Read more »
I am a biotech VC, but not a techie. So I don’t follow stem cells, gene therapy, and other similar “blockbuster” technologies in the life sciences. Rather than looking at all... Read more »
In his Life Sci VC blog, Bruce Booth recently wrote “Biotech is back with a vengeance in this IPO window.” It’s an accurate snapshot of the market, but the good times... Read more »
I find myself siding more with Flagship’s Noubar Afeyan than with Katrine Bosley in the intriguing conversation emerging in Xconomy in recent weeks over the supply chain model for early stage... Read more »
As Washington grapples with the deficit, nothing generates more emotion than tax “loopholes.” A priority “loophole” target in the budget that President Obama sent to Congress last week is the treatment... Read more »
Third Rock Ventures was in the enviable position of turning away some institutional investors when the life sciences venture firm recently closed on $516 million for its third venture fund.
So... Read more »
© 2007-2016, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.